PLx Pharma Inc.
NASDAQ: PLXP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Natasha Giordano
- Employees
- 16
- Headquarters
- Sparta, United States
- IPO year
- 2014
- Market cap
- $2.5M
- Website
- https://plxpharma.com
Loading PLXP…
Loading profile data…Frequently asked questions about PLXP
What does PLx Pharma Inc. (PLXP) do?
PLx Pharma Inc. is a U.S.-based entity leveraging its innovative drug delivery platform technology, having successfully transitioned into the commercial stage. The company's primary offerings include Vazalore 325 mg, which is formulated for individuals facing vascular incidents like heart attacks and clot-induced strokes, as well as for the mana...
Where does PLXP trade?
PLx Pharma Inc. (PLXP) trades on the NASDAQ Capital Market.
What sector is PLXP in?
PLx Pharma Inc. (PLXP) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of PLx Pharma Inc.?
Natasha Giordano is the chief executive officer of PLx Pharma Inc. (PLXP).
Where is PLx Pharma Inc. headquartered?
PLx Pharma Inc. is headquartered in United States.
Does PLXP pay a dividend?
PLx Pharma Inc. (PLXP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PLXP go public?
PLx Pharma Inc. (PLXP) completed its initial public offering in 2014.